Fig. 8From: Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centersSchematic representation depicting a possible favorable effect of combinatorial treatment with CGRP mAbs, which mainly act mainly at peripheral sites, and centrally acting preventive drugs, such as Ca2+ blockers, tricyclic antidepressants (TCAs), and antiepileptic drugs (AEDs)Back to article page